OrganiGram Reports Record Revenue and Expansion

OrganiGram Holdings ( (OGI) ) has released its Q3 earnings. Here is a breakdown of the information OrganiGram Holdings presented to its investors.

OrganiGram Holdings, a leading cannabis company in Canada, is renowned for its production of high-quality, indoor-grown cannabis for both medical and recreational use, with a focus on expanding its international footprint.

In its latest earnings report for the third quarter of fiscal 2025, OrganiGram announced record revenues, marking the second consecutive quarter of such achievement. The company highlighted significant growth in adjusted EBITDA, free cash flow, and international expansion, underscoring its strong market presence in Canada and its strategic moves into the U.S. market.

Key financial metrics revealed a 73% year-over-year increase in gross revenue to $110.2 million, with net revenue climbing 72% to $70.8 million. The company’s adjusted EBITDA rose by 64% to $5.7 million, and it reported a positive free cash flow of $5.0 million, a substantial improvement from the previous year. OrganiGram also achieved a record harvest at its Moncton facility and expanded its product distribution across Canada and the U.S.

Despite a net loss of $6.3 million, attributed to fair value changes in financial instruments, the company remains optimistic about future profitability. The integration of recent acquisitions, such as Motif Labs, is expected to enhance synergies and improve margins in upcoming quarters.

Looking ahead, OrganiGram’s management is confident in its trajectory toward sustained profitability, driven by its strong market leadership in Canada and strategic international expansions. The company aims to leverage its innovative product portfolio and operational efficiencies to capture additional market share globally.